Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy
| Autor: | Mehmet Reyhan, Ezgi Oymak, Nese Torun, Ali Fuat Yapar, Cem Onal, Ozan Cem Guler |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.diagnostic_test business.industry medicine.medical_treatment Urology General Medicine urologic and male genital diseases medicine.disease Primary tumor 030218 nuclear medicine & medical imaging Radiation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine medicine.anatomical_structure Antigen Prostate Positron emission tomography 030220 oncology & carcinogenesis Glutamate carboxypeptidase II Medicine Radiology Nuclear Medicine and imaging business Lymph node |
| Zdroj: | Annals of Nuclear Medicine. 34:388-396 |
| ISSN: | 1864-6433 0914-7187 |
| Popis: | The aim of the study is to investigate the correlation between the intensity of prostate-specific membrane antigen (PSMA) uptake in primary tumor and clinico-pathological characteristics of non-metastatic prostate cancer patients treated with definitive radiotherapy (RT). Using the clinical data of 201 prostate cancer patients who were referred for 68 Ga-PSMA-positron emission tomography (PET/CT) for staging and RT planning, we analyzed the correlations among intermediate- or high-risk disease based on Gleason score (GS), prostate-specific antigen (PSA) level, D’Amico risk group classification, and maximum standardized uptake (SUVmax) of primary tumor. Primary tumor was visualized via 68 Ga-PSMA-PET/CT scan in 192 patients (95.5%). The median SUVmax of primary tumor and metastatic lymph node were 13.2 (range 3.3–83.7) and 11.4 (range 3.6–64.5), respectively. A significant moderate correlation was observed between PSA level and median tumor SUVmax as measured by 68 Ga-PSMA-PET/CT (Spearman = 0.425; p 10 ng/mL, GS > 7, D’Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher tracer uptake in primary tumor than their counterparts. The median SUVmax of primary tumor was highest in patients with GS 9. The primary tumor detection rates of 68 Ga-PSMA-PET/CT were 83%, 92%, and 99% for patients with serum PSA ≤ 5.0 ng/mL (14 patients, 7%), PSA 5.1–10.0 ng/mL (45 patients, 22%), and PSA > 10 ng/mL (142 patients, 71%), respectively. We demonstrated a correlation between prostate tumor characteristics and PSMA tracer uptake. Patients with serum PSA > 10 ng/mL, GS > 7, D’Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher SUV than their counterparts. In addition, the primary tumor detection rate was higher in patients with serum PSA > 10 ng/mL and GS > 7. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink